Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • PMBJPs generic drugs...

    PMBJPs generic drugs upto 96 percent cheaper than branded equivalents

    Written by Ruby Khatun Khatun Published On 2018-01-03T12:30:08+05:30  |  Updated On 3 Jan 2018 12:30 PM IST
    PMBJPs generic drugs upto 96 percent cheaper than branded equivalents

    New Delhi: The government is selling generic medicines at prices cheaper by up to 96 percent compared to their branded generic equivalents through its Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) Kendras, Parliament was informed.


    In a written reply to a query in the Lok Sabha, Minister of State for Chemicals and Fertilisers Mansukh L Mandaviya said: "Branded generic medicines are generally sold at higher prices in comparison to their unbranded generic equivalents."


    Giving a list of price comparison, he said Gemcitabine 1,000 mg vial injection used for the treatment of bladder cancer has an average market price of Rs 6,412.04 for three top brands, but the PMBJP price is Rs 631.21, a saving of 90.15 percent for the patients.


    Similarly, commonly used atorvastatin 10 mg 10 tablets (cholesterol lowering) are sold at Rs 8.02 in the PMBJPs while the average market price of top three brands is Rs 70. This provides a saving of Rs 88.54 percent, the minister added.


    Tadalafil 20 mg 4 tablets (used for the treatment of erectile dysfunction) that have an average market price of Rs 209.43 for top three branded medicines are being sold at Rs 7.63 in PMBJPs, which is 96.35 percent cheaper.


    As on December 27, 2017, there are 3,033 functional PMBJP Kendras in the country, Mandaviya said.

    96 percent cheaperAtorvastatinbladder cancerbranded equivalentscholesterol lowering drugdrugserectile dysfunctionGemcitabineInjectionLok SabhaMansukh L MandaviyaMinister of State for Chemicals and FertilisersParliamentPMBJPPradhan Mantri Bhartiya Janaushadhi Pariyojana schemesellingtadalafil
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok